Sonoma pharmaceuticals regains compliance with nasdaq minimum bid price rule

Boulder, co / accesswire / september 19, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it received a formal determination letter from nasdaq notifying sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the nasdaq capital market and the matter is now closed. as previously reported, on september 22, 2023, sonoma received a letter from nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the nasdaq capital market.
SNOA Ratings Summary
SNOA Quant Ranking